“the quit rate for varenicline alone in this sample is highly encouraging, as this is the first large-scale trial of varenicline efficacy focused solely on heavy-drinking smokers,” ray said.
while the two drugs were not as effective at stopping smoking when used in combination, they fared better at slowing alcohol consumption than the placebo group. prior to the study, participants were averaging almost seven alcoholic beverages per drinking day; after the study, subjects who were given both varenicline and naltrexone dropped consumption to just three beverages per week over the 12-week period of study. those given varenicline plus a placebo reduced consumption to four drinks per week.
“i am excited about both the smoking cessation rates and the drinking reductions,” ray said. “these findings suggests that desirable outcomes for smoking cessation and drinking reduction are achievable.”
drinking and smoking — two major health risks that can impact the quality of life and longevity — often go hand in hand with around 20 to 25 per cent of smokers also engaging in heavy drinking, according to the study. both habits are associated with worse health outcomes when covid-19 enters the picture.
the findings, which were consistent across gender, showed prescription drugs can play a powerful role in halting unhealthy habits, ray said. managing multiple medications can be difficult for patients, however, and may not be necessary in this case.
“varenicline alone is doing a great job and this trial indicates that there is not much room for naltrexone to make a difference,” she said. “but even medications like varenicline have their limitations. medication is only part of the solution. there remains much research to be done on addictions and how to treat them.”
for people struggling to get their alcohol and nicotine use under control, this could be an effective option to discuss with a doctor, she said. “there is evidence that varenicline can help them with both. varenicline appears quite effective at reducing drinking and helping people to quit smoking. given that varenicline has been found to reduce drinking in trials for alcohol use disorder, it is possible that its effects on both drinking and smoking present an optimal alternative for this group of heavy-drinking smokers.”